These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35064389)

  • 21. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
    Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER
    AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
    Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women's motivations for participating in the dapivirine vaginal ring open label extension study.
    Naidoo K; Montgomery ET; Katz AWK; Garcia M; Naidoo S; Mansoor LE
    AIDS Care; 2024 Mar; 36(3):326-342. PubMed ID: 37734338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of dapivirine vaginal ring for HIV prevention.
    Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
    Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
    Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
    AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
    Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
    AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
    Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
    AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women.
    Gollub EL; Vaughan R
    AIDS Educ Prev; 2022 Aug; 34(4):311-324. PubMed ID: 35994576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
    Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
    J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
    McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P
    Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study.
    van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P;
    J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
    Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
    AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
    Hartmann M; Palanee-Phillips T; O'Rourke S; Adewumi K; Tenza S; Mathebula F; Wagner D; Ayub A; Montgomery ET
    AIDS Care; 2019 Jun; 31(6):660-666. PubMed ID: 30309246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
    Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
    AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
    Shapley-Quinn MK; Laborde N; Luecke E; Hoesley C; Salata RA; Johnson S; Nel A; Soto-Torres L; Chen BA; van der Straten A
    AIDS Patient Care STDS; 2022 Mar; 36(3):97-105. PubMed ID: 35289688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brief Report: Dapivirine Ring HIV-1 Prevention Effectiveness for Women Engaged in Vaginal and Anal Intercourse: Insights From Mathematical Modeling.
    Peebles K; Brown ER; Hendrix CW; Palanee-Phillips T; van der Straten A; Harkoo I; Reddy K; Mirembe BG; Jeenarain N; Hillier SL; Baeten JM; Barnabas RV;
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):122-126. PubMed ID: 36184755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.